NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/13/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization227.32 mln
Float20.01 mln
Earnings Date08/06/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
1044
Highly suspicious
1-Year Forecast
29.60
Transformational upside
Relative Strength
96
/ 100
Top performer
Debt / Equity
0.08
Debt-free
ROE
-80.66
Deeply negative
Business Description
Precision BioSciences is a US-based medical research company focused on developing treatments that work by editing the DNA inside living patients. Founded in 2006 and based in Durham, North Carolina, the company has built its own gene editing technology, called ARCUS, which it uses to target and modify specific sections of genetic material. Its current pipeline includes experimental treatments for chronic hepatitis B, Duchenne muscular dystrophy, a rare mitochondrial condition, and an inherited liver disorder, with additional work underway through partnerships with other biotechnology firms.
